Cervical Cancer
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
- Details
ClinicalTrials.gov ID:
NCT03894215
Diagnosis Type:
NA
USOR Number:
- Address
,
P:
